Trials / Recruiting

RecruitingNCT06893016

Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study Evaluating the Safety, Tolerability, and Efficacy of RAY1225 in Participants Who Have Obesity or Are Overweight

Status: Recruiting
Phase: Phase 3
Study type: Interventional
Enrollment: 640 (estimated)

Sponsor: Guangdong Raynovent Biotech Co., Ltd · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The primary objective of this study is to demonstrate that RAY1225 is superior to placebo for percent change in body weight.

Conditions

Obesity

Interventions

Type	Name	Description
DRUG	RAY1225	RAY1225 will be administered SC
DRUG	Placebo	Placebo will be administered SC.

Timeline

Start date: 2025-06-15
Primary completion: 2026-06-15
Completion: 2026-09-15
First posted: 2025-03-25
Last updated: 2025-07-17

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06893016. Inclusion in this directory is not an endorsement.